Skip to main content
. 2019 Mar 4;11(4):e9695. doi: 10.15252/emmm.201809695

Figure 4. Acitretin increases APP but not NrCAM shedding in primary neurons and AD patients.

Figure 4

  • A
    Wt neurons were kept in culture until DIV5; then, the cells were treated with acitretin (4 μM) or vehicle control for 48 h, as described earlier (Tippmann et al, 2009).
  • B
    Densitometric quantifications of the Western blots are shown (***P < 0.001; ****P < 0. 0001, two‐sided Student's t‐test, n = 9–20). The mean levels of solvent‐treated cells were set to 1.
  • C
    Detection of sNrCAM and human serum albumin (hSA) in AD patients CSF that had been treated with acitretin (30 mg/day) or placebo for 30 days (n = 9) (Endres et al, 2014). b = baseline; t = treatment.
  • D
    Densitometric quantification of the Western blots in (C). sNrCAM/hSA ratios were calculated, and then, the treatment‐to‐baseline (t/b) ratios for every patient were calculated. Two‐sided Student's t‐test (n = 9).
Data information: Given are mean ± the standard error of the mean. Representative Western blots are shown.Source data are available online for this figure.